Mar 4, 2011 · Clinically, mutations in the MEN1 and DAXX/ATRX genes were associated with better prognosis. We also found mutations in genes in the mTOR (mammalian target of …

Apr 1, 2022 · In sporadic PanNENs, driver mutations in MEN1, DAXX/ATRX and mTOR pathway genes are associated with development and progression in pancreatic neuroendocrine tumours.

mTOR acts as the catalytic subunit of two large complexes, mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). These complexes have different upstream and downstream …

May 19, 2013 · Patients with genetic mutations and loss in PTEN, TSC2, NF1, and vHL genes have implicated the role of the PI3K–Akt–mTOR pathway in neuroendocrine tumors, the …

Jun 1, 2017 · On this basis we reviewed m-TOR inhibitors in pNETs, focusing on their mechanisms of resistance and toxicity. Pancreatic neuroendocrine tumors (pNETs) are rare …

Recent genetic studies have highlighted that alterations in MEN1, chromatin remodeling genes, and mammalian target of rapamycin (mTOR) pathway genes are the most frequent molecular …

Nov 14, 2024 · The incidence and prevalence of pancreatic neuroendocrine neoplasms are steadily increasing. These tumors are highly heterogeneous, with treatment options ranging …

Aug 1, 2019 · Despite having a low background mutation rate, driver mutations in MEN1, DAXX/ATRX and mTOR pathway genes (PTEN, TSC1/2) are implicated in disease …

Dec 3, 2020 · TSC is an autosomal-dominant, multisystem disorder. It is caused by mutations of 2 tumor-suppressor genes, TSC1 on chromosome 9q34, which encodes hamartin, and TSC2 on …

With the development of the new-generation mTOR inhibitor everolimus, a series of clinical trials over the last 5 years have demonstrated significant benefit in delaying tumor progression.